p53基因在宫颈癌发病中的意义及对放射敏感性的影响

doi:10.3760/cma.j.issn.1004-4221.2017.05.025

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (830 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

放疗在宫颈癌治疗中具有重要地位,但放疗抵抗导致局部未控仍常见,因此预测放射敏感性对制定个体化治疗策略是非常有益的。影响放射敏感性的因素有很多,p53状态是重要因素之一,p53基因上下游信号分子的调控亦能影响宫颈癌放射敏感性。本文分析了p53基因在不同宫颈癌中的差异,并探讨p53调控放射敏感性的可能方式。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李平
	陈敏斌

关键词 ： p53基因, 宫颈癌, 放射敏感性, 调控

Abstract：

Radiotherapy is a major local treatment for cervical cancer. However, local uncontrollability due to radioresistance is still common. Therefore, the prediction of radiosensitivity is quite beneficial to develop an optimal treatment strategy for individual patients. Multiple factors could influence the radiosensitivity of cells, and p53 status is one of them. The upstream or downstream molecules of p53 could also be regulated to affect the radiosensitivity of cervical cancer. The aim of the review is to analyze the difference in p53 status between different types of cervical cancer and to discuss how p53 regulates the response to radiotherapy.

Key words： p53 gene Cervical neoplasms Radiosensitivity Regulate

收稿日期: 2016-04-18

基金资助:

国家自然科学面上基金(81472786);昆山市宫颈癌综合诊疗的全程管理(LCZX201619)

通讯作者: 陈敏斌,Email:cmb1981@163.com

引用本文:

李平,陈敏斌. p53基因在宫颈癌发病中的意义及对放射敏感性的影响[J]. 中华放射肿瘤学杂志, 2017, 26(5): 593-597.

Li Ping,Chen Minbin. Significance of p53 in cervical cancer and its influence on radiosensitivity[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 593-597.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2017.05.025 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2017/V26/I5/593

[1] Madhumati G,Kavita S,Anju M,et al. Immunohistochemical Expression of Cell Proliferating Nuclear Antigen (PCNA) and p53 Protein in Cervical Cancer[J].J Obstet Gynaecol India,2012,62(5):557-61.DOI:10.1007/s13224-012-0180-6.
[2] Song L,Liu S,Zeng S,et al.miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway[J].Med Sci Monit,2015,21:2210-7.DOI:10.12659/MSM.893859.
[3] Liu L,Li XD,Chen HY,et al. Significance of Ebp1 and p53 protein expression in cervical cancer[J].Genet Mol Res,2015,14(4):11860-6.DOI:10.4238/2015.October.2.19.
[4] Uchiyama M,Iwasaka T,Matsuo N,et al. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix[J].Gynecol Oncol,1997,65(1):23-9.DOI:10.1006/gyno.1997.4613.
[5] Kastan MB,Berkovich E.p53:a two-faced cancer gene[J].Nat Cell Biol,2007,9(5):489-91.DOI:10.1038/ncb0507-489.
[6] 钱鑫.DNA放射损伤与p53[J].生理科学进展,2005,36(4):379-381.Qian X.DNA radiation injury and p53[J].Adv Physiol Sci[J].2005,36(4):379-381.
[7] Kim JW,Cho YH,Lee C G,et al. Human papillomavirus infection and TP53 gene mutation in primary cervical carcinoma[J].Acta Oncol,1997,36(3):295-300.
[8] Crook T,Wrede D,Tidy J A,et al. Clonal p53 mutation in primary cervical cancer:association with human-papillomavirus-negative tumours[J].Lancet,1992,339(8801):1070-1073.
[9] Ojesina AI,Lichtenstein L,Freeman SS,et al. Landscape of genomic alterations in cervical carcinomas[J].Nature,2014,506(7488):371-5.DOI:10.1038/nature12881.
[10] Andersson S,Hellstrom A C,Ren Z P,et al. The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas[J].Med Oncol,2006,23(1):113-9.DOI:10.1385/MO:23:1:113.
[11] Fujita M,Inoue M,Tanizawa O,et al. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection[J].Cancer Res,1992,52(19):5323-8.
[12] 张美琴,蔡树模,施达仁.子宫颈鳞癌和腺癌的放射敏感性比较[J].中华妇产科杂志,1998,33(10):611-613.DOI:10.3760/j.issn:0529-567X.1998.10.010.
Zhang MQ,Chai SM,Shi DR.Comparison of radiosensitivity of cervical squamous cell carcinoma and adenocarcinoma[J].Chin J Obst Gynecol,1998,33(10):611-613.DOI:10.3760/j.issn:0529-567X.1998.10.010.
[13] Tornesello ML,Buonaguro L,Buonaguro FM.Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix:a systematic review[J].Gynecol Oncol,2013,128(3):442-8.DOI:10.1016/j.ygyno.2012.11.017.
[14] Tenti P,Pavanello S,Padovan L,et al. Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix[J].Am J Pathol,1998,152(4):1057-63.
[15] Andersson S,Hellstr m AC,Ren ZP,et al. The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas[J].Med Oncol,2006,23(1):113-119.
[16] Bahnassy AA,Zekri AR,Saleh M,et al. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma[J].BMC Clin Pathol,2007,7:4.DOI:10.1186/1472-6890-7-4.
[17] Wootipoom V,Lekhyananda N,Phungrassami T,et al. Prognostic significance of Bax,Bcl-2,and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy[J].Gynecol Oncol,2004,94(3):636-42.DOI:10.1016/j.ygyno.2004.03.012.
[18] Dellas A,Schultheiss E,Almendral AC,et al. Altered expression of mdm-2 and its association with p53 protein status,tumor-cell-proliferation rate and prognosis in cervical neoplasia[J].Int J Cancer,1997,74(4):421-5.
[19] Tee YT,Wang PH,Yang SF,et al. Lymph node metastases,not human telomerase reverse transcriptase or p53 proteins,as the strongest prognostic factor for survival in early stage cervical cancer[J].J Obstet Gynaecol Res,2008,34(6):1002-9.DOI:10.1111/j.1447-0756.2008.00861.x.
[20] Turkcuoglu I,Tezcan S,Kaygusuz G,et al. The role of p53,Bcl-2 and Ki-67 in premalignant cervical lesions and cervical cancer[J].Eur J Gynaecol Oncol,2007,28(4):290-3.
[21] Bremer GL,Tieboschb AT,Putten HW,et al.p53 tumor suppressor gene protein expression in cervical cancer:relationship to prognosis[J].Eur J Obst Gynecol Reprod Biol,1995,63(1):55.
[22] Huang LW,Chou YY,Chao SL,et al.p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix:overexpression of p53 predicts poor disease outcome[J].Gynecol Oncol,2001,83(2):348-54.DOI:10.1006/gyno.2001.6397.
[23] Cardillo MR,Stamp GW,Pignatelli MN,et al. Immunohistochemical analysis of p53 oncoprotein and proliferating cell nuclear antigen (PCNA) in the cervix uteri[J].Eur J Gynaecol Oncol,1993,14(6):484-490.
[24] Jain D,Srinivasan R,Patel FD,et al. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage Ⅱ_{b/Ⅲ patients treated by radiotherapy[J].Gynecol Oncol,2003,88(1):22-28.

[25] Brenna SM,Zeferino LC,Pinto GA,et al.p53 expression as a predictor of recurrence in cervical squamous cell carcinoma[J].Int J Gynecol Cancer,2002,12(3):299-303.

[26] Dimitrakakis C,Kymionis G,Diakomanolis E,et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions[J].Gynecol Oncol,2000,77(1):129-36.DOI:10.1006/gyno.1999.5715.

[27] Kainz C,Kohlberger P,Gitsch G,et al. Mutant p53 in patients with invasive cervical cancer stages Ⅰ_B to Ⅱ_B[J].Gynecol Oncol,1995,57(2):212-214.DOI:10.1006/gyno.1995.1127.

[28] Mega-Tiber P,Baloglu L,Ozden S,et al. The association of apoptotic protein expressions sensitive to apoptosis gene,p73 and p53 with the prognosis of cervical carcinoma[J].Oncol Targ Ther,2014,7:2161-8.DOI:10.2147/OTT.S71448.DOI:10.2147/OTT.S71448.

[29] Romus I,Triningsih FE,Mangunsudirdjo S,et al. Clinicopathology significance of p53 and p63 expression in Indonesian cervical squamous cell carcinomas[J].Asian Pac J Cancer Prev,2013,14(12):7737-7741.

[30] Zhou R,Wei C,Liu J,et al. The prognostic value of p53 expression for patients with cervical cancer:a meta analysis[J].Eur J Obstet Gynecol Reprod Biol,2015,195:210-213.DOI:10.1016/j.ejogrb.2015.10.006.

[31] Raybauddiogène H,Fortin A,Morency R,et al. Markers of radioresistance in squamous cell carcinomas of the head and neck:a clinicopathologic and immunohistochemical study[J].J Clin Oncol,1997,15(5):1030-8.DOI:10.1200/JCO.1997.15.3.1030.

[32] Tatemoto Y,Osaki T,Yoneda K,et al. Expression of p53 and p21 proteins in oral squamous cell carcinoma:correlation with lymph node metastasis and response to chemoradiotherapy[J].Pathol Res Pract,1998,194(12):821-830.DOI:10.1016/S0344-0338(98)80084-8.

[33] Chai R,Yu ZQ,Fu CG,et al. Preliminary study on relationship between multi-drug resistance-associated protein 4 and radiosensitivity of rectal cancer[J].Chin J Gastrointest Surgery,2011,14(8):627-630.

[34] Chen MB,Wu XY,Yu R,et al.p53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment:a meta-analysis in rectal cancer[J/OL].PLoS One,2012,7(9):e45388.DOI:10.1371/journal.pone.0045388.

[35] Oka K,Suzuki Y,Nakano T.Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone:radiotherapeutic effect and prognosis[J].Cancer,2000,88(12):2766-2773.

[36] Fu Z,Chen D,Cheng H,et al. Hypoxia-inducible factor-1alpha protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia[J].Med Sci Monit,2015,21:318-25.DOI:10.12659/MSM.893265.

[37] Omori M,Hashi A,Kondo T,et al. Dysregulation of CDK inhibitors and p53 in HPV-negative endocervical adenocarcinoma[J].Int J Gynecol Pathol,2015,34(2):196-203.DOI:10.1097/PGP.0000000000000121.

[38] King SA,Adas AA,Livolsi VA,et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma[J].Cancer,1995,75(11):2700-2705.

[39] Cheng G,Kong D,Hou X,et al. The tumor suppressor,p53,contributes to radiosensitivity of lung cancer cells by regulating autophagy and apoptosis[J].Cancer Biother Radiopharm,2013,28(2):153-159.DOI:10.1089/cbr.2012.1297.

[40] Lindel K,Rieken S,Daffinger S,et al. The transcriptional regulator gene E2 of the Human Papillomavirus (HPV) 16 influences the radiosensitivity of cervical keratinocytes[J].Radiat Oncol,2012,7:187.DOI:10.1186/1748-717X-7-187.

[41] Pang E,Delic NC,Hong A,et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6^*I[J].Int J Radiat Oncol Biol Phys,2011,79(3):860-865.DOI:10.1016/j.ijrobp.2010.06.028.

[42] Liu ZG,Zhao LN,Liu YW,et al. Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents[J].J Mol Biol,2007,374(2):334-45.DOI:10.1016/j.jmb.2007.09.031.

[43] Shin HJ,Kim JY,Hampson L,et al. Human papillomavirus 16 E6 increases the radiosensitivity of p53-mutated cervical cancer cells,associated with up-regulation of aurora A[J].Int J Radiat Biol,2010,86(9):769-79.DOI:10.3109/09553002.2010.484477.

[44] Hampson L,El Hady ES,Moore JV,et al. The HPV₁₆ E6 and E7 proteins and the radiation resistance of cervical carcinoma[J].Faseb J,2001,15(8):1445-1447.

[45] Jung HS,Rajasekaran N,Song SY,et al. Human papillomavirus e6/e7-specific sirna potentiates the effect of radiotherapy for cervical cancer in vitro and in vivo[J].Int J Mol Sci,2015,16(6):12243-12260.DOI:10.3390/ijms160612243.

[46] Deweese TL,Walsh JC,Dillehay LE,et al. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation[J].Int J Radiat Oncol Biol Phys,1997,37(1):145.

[47] Abraham PT,Eduardo LU,Verónica GC,et al. MicroRNAs in cervical cancer:evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance[J].Molecules,2014,19(5):6263-6281.DOI:10.3390/molecules19056263.

[48] Zhang J,Shen L,Sun L Q.The regulation of radiosensitivity by p53 and its acetylation[J].Cancer Lett,2015,363(2):108-118.DOI:10.1016/j.canlet.2015.04.015.

[49] Knappskog S,Lnning P E.MDM₂ SNP309 and risk of cervical cancer[J].Tumour Biol J Int Soc Oncodevel Biol Med,2014,35(7):6185-6186.DOI:10.1007/s13277-014-1910-4.

[50] Werner LR,Huang S,Francis DM,et al. Small molecule inhibition of MDM₂-p53 interaction augments radiation response in human tumors[J].Mol Cancer Therapeut,2015,14(9).DOI:10.1158/1535-7163.MCT-14-1056-T.

[51] Zhao Y,Aguilar A,Bernard D,et al. Small-molecule inhibitors of the MDM₂-p53 protein-protein interaction (MDM₂ Inhibitors) in clinical trials for cancer treatment[J].J Med Chem,2015,58(3):1038-52.DOI:10.1021/jm501092z.

[52] Li J,Wang Y,Dong R,et al. HOTAIR enhanced aggressive biological behaviors and induced radio-resistance via inhibiting p21 in cervical cancer[J].Tumour Biol J Int Soc Oncodevel Biol Med,2015,36(5):1-9.DOI:10.1007/s13277-014-2998-2.

[53] Woo SJ,Kim MJ,Kim RK,et al. A new 2-pyrone derivative,5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one,synergistically enhances radiation sensitivity in human cervical cancer cells[J].Anti-Cancer Drug,2012,23(23):43-50.DOI:10.1097/CAD.0b013e32834a66ef.

[54] Sanli T,Rashid A,Liu C,et al. Ionizing radiation activates AMP-activated kinase (AMPK):a target for radiosensitization of human cancer cells[J].Int J Radiat Oncol Biol Phys,2010,78(1):221-229.DOI:10.1016/j.ijrobp.2010.03.005.

[55] Muaddi H,Chowdhury S,Vellanki R,et al. Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin[J].Radiother Oncol,2013,108(3):446-50.DOI:10.1016/j.radonc.2013.06.014.

[56] Jones RG,Plas DR,Kubek S,et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint[J].Mol Cell,2005,18(3):283-293.DOI:10.1016/j.molcel.2005.03.027.

[57] Sanli T,Steinberg GR.AMP-activated protein kinase (AMPK) beyond metabolism,a novel genomic stress sensor participating in the DNA damage response pathway[J].Cancer Biol Ther,2013,15(2):156-169.DOI:10.4161/cbt.26726.}